These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 8624641)

  • 61. A randomized placebo-controlled trial of methotrexate in psoriatic arthritis.
    Kingsley GH; Kowalczyk A; Taylor H; Ibrahim F; Packham JC; McHugh NJ; Mulherin DM; Kitas GD; Chakravarty K; Tom BD; O'Keeffe AG; Maddison PJ; Scott DL
    Rheumatology (Oxford); 2012 Aug; 51(8):1368-77. PubMed ID: 22344575
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Comparison of two different folic acid doses with methotrexate--a randomized controlled trial (FOLVARI Study).
    Dhir V; Sandhu A; Kaur J; Pinto B; Kumar P; Kaur P; Gupta N; Sood A; Sharma A; Sharma S
    Arthritis Res Ther; 2015 Jun; 17(1):156. PubMed ID: 26063325
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
    Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
    Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial.
    Lv QW; Zhang W; Shi Q; Zheng WJ; Li X; Chen H; Wu QJ; Jiang WL; Li HB; Gong L; Wei W; Liu H; Liu AJ; Jin HT; Wang JX; Liu XM; Li ZB; Liu B; Shen M; Wang Q; Wu XN; Liang D; Yin YF; Fei YY; Su JM; Zhao LD; Jiang Y; Li J; Tang FL; Zhang FC; Lipsky PE; Zhang X
    Ann Rheum Dis; 2015 Jun; 74(6):1078-86. PubMed ID: 24733191
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: the HIKARI randomized, placebo-controlled trial.
    Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Iwai K; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
    Mod Rheumatol; 2014 Jul; 24(4):552-60. PubMed ID: 24981319
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial.
    Emery P; Fleischmann RM; Strusberg I; Durez P; Nash P; Amante EJ; Churchill M; Park W; Pons-Estel B; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    Arthritis Care Res (Hoboken); 2016 Jun; 68(6):744-52. PubMed ID: 26474452
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
    Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
    Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
    Takeuchi T; Miyasaka N; Zang C; Alvarez D; Fletcher T; Wajdula J; Yuasa H; Vlahos B
    Mod Rheumatol; 2013 Jul; 23(4):623-33. PubMed ID: 23011358
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate.
    Rigby W; Ferraccioli G; Greenwald M; Zazueta-Montiel B; Fleischmann R; Wassenberg S; Ogale S; Armstrong G; Jahreis A; Burke L; Mela C; Chen A
    Arthritis Care Res (Hoboken); 2011 May; 63(5):711-20. PubMed ID: 21557525
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Low-dose methotrexate in the treatment of widespread morphea.
    Seyger MM; van den Hoogen FH; de Boo T; de Jong EM
    J Am Acad Dermatol; 1998 Aug; 39(2 Pt 1):220-5. PubMed ID: 9704833
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Safety and Efficacy of Subcutaneous Golimumab in Patients with Active Rheumatoid Arthritis despite Methotrexate Therapy: Final 5-year Results of the GO-FORWARD Trial.
    Keystone EC; Genovese MC; Hall S; Bae SC; Han C; Gathany TA; Xu S; Zhou Y; Leu JH; Hsia EC
    J Rheumatol; 2016 Feb; 43(2):298-306. PubMed ID: 26669912
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of fostamatinib, an oral spleen tyrosine kinase inhibitor, in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Weinblatt ME; Genovese MC; Ho M; Hollis S; Rosiak-Jedrychowicz K; Kavanaugh A; Millson DS; Leon G; Wang M; van der Heijde D
    Arthritis Rheumatol; 2014 Dec; 66(12):3255-64. PubMed ID: 25223724
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Methotrexate treatment in hand osteoarthritis refractory to usual treatments: A randomised, double-blind, placebo-controlled trial.
    Ferrero S; Wittoek R; Allado E; Cruzel C; Fontas E; Breuil V; Ziegler L; Kremer J; Loeuille D; Roux CH
    Semin Arthritis Rheum; 2021 Aug; 51(4):831-838. PubMed ID: 34157578
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial.
    St Clair EW; van der Heijde DM; Smolen JS; Maini RN; Bathon JM; Emery P; Keystone E; Schiff M; Kalden JR; Wang B; Dewoody K; Weiss R; Baker D;
    Arthritis Rheum; 2004 Nov; 50(11):3432-43. PubMed ID: 15529377
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study.
    Mease PJ; Gladman DD; Keystone EC;
    Arthritis Rheum; 2006 May; 54(5):1638-45. PubMed ID: 16646026
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound.
    Karalilova RV; Batalov ZA; Sapundzhieva TL; Matucci-Cerinic M; Batalov AZ
    Rheumatol Int; 2021 Oct; 41(10):1743-1753. PubMed ID: 34313812
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Pulmonary Adverse Events in Patients Receiving Low-Dose Methotrexate in the Randomized, Double-Blind, Placebo-Controlled Cardiovascular Inflammation Reduction Trial.
    Sparks JA; Dellaripa PF; Glynn RJ; Paynter NP; Xu C; Ridker PM; Solomon DH
    Arthritis Rheumatol; 2020 Dec; 72(12):2065-2071. PubMed ID: 32741143
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.